Awards & Advancement

Edward Lanphier elected chairman of the Alliance for Regenerative Medicine

Thursday, November 13, 2014 02:15 PM

Sangamo BioSciences has announced that Edward Lanphier, the company's president and CEO, has been elected as the next chairman of the Alliance for Regenerative Medicine (ARM). Wash. D.C.-based ARM is an international organization that represents and supports industry, clinical institutions, patient advocates and other stakeholders in the development of safe and effective gene and cell therapies. Lanphier succeeds Geoff MacKay, president and CEO of Organogenesis, who will complete his two-year term as chairman on Dec. 31.

More... »


inVentiv Health names Jeffrey Wilks president of advertising

Thursday, November 13, 2014 02:10 PM

inVentiv Health, a life science knowledge and services company for the new healthcare environment, has appointed of Jeffrey Wilks as president of its advertising businesses. Wilks will report to Mike Griffith, executive vice president, inVentiv Health and president, inVentiv Commercial.

More... »


Greenphire Joins the Deloitte 2014 Technology Fast 500

Thursday, November 13, 2014 01:49 PM

Greenphire, a provider of payment technology for the clinical trials industry, has won a place in Deloitte's 2014 Technology Fast 500. Ranking 48th in the annual list of the fastest growing technology companies in the U.S, Greenphire secured its place as a result of an exceptional 2782% growth over the past four years.

More... »

Stephen T. Sonis joins PlasmaTech Biopharmaceuticals' scientific advisory board

Friday, November 7, 2014 02:07 PM

PlasmaTech Biopharmaceuticals, a biopharmaceutical company advancing patient care in critical areas, has announced that Stephen T. Sonis, DMD, DMSc, has joined its scientific advisory board (SAB). A world-renowned expert in the clinical treatment and research of cancer-related mucosal toxicities, Sonis has collaborated with management in recent years on advancing the company's clinical efforts of its oral mucositis treatment, MuGard.

More... »

Cloud Pharmaceuticals ratifies board of directors

Friday, November 7, 2014 01:42 PM

Cloud Pharmaceuticals, a therapeutics company focused on cloud-based drug design and development, has ratified its board of directors. Members of the board include Cloud Pharmaceuticals chairman and CEO Ed Addison, chief scientific officer Shahar Keinan, Ph.D., and chief information officer Lawrence Husick. Other members of the board include:

More... »

Lexicon expands management

Thursday, November 6, 2014 03:13 PM

Lexicon Pharmaceuticals has announced management additions directed toward the completion of phase III development and commercial preparations for telotristat etiprate in carcinoid syndrome and preparation for phase III initiation and commercial readiness for sotagliflozin (LX4211) in type 1 diabetes.

More... »

CluePoints wins ENTENTE Life Science Investment Forum Award

Thursday, October 30, 2014 01:32 PM

CluePoints, a provider of Centralized Statistical Monitoring (CSM) solutions for clinical trials, has secured an ENTENTE Life Science Investment Forum Award. The award program, which is organized by the ENTENTE project and supported by the European Commission and EuropaBio, recognized CluePoints as one of Belgium's most innovative high technology businesses for its Central Statistical Monitoring (CSM) solution, which employs unique statistical algorithms to determine the quality, accuracy and integrity of clinical trial data.

More... »

ERT named innovation award recipient by Philadelphia Business Journal

Monday, October 27, 2014 01:32 PM

ERT, a global solution provider for high-quality patient safety and efficacy endpoint data collection, has been honored as a 2014 Innovation Award Recipient by the Philadelphia Business Journal. The awards program recognizes the region’s leading companies for their innovations in the fields of healthcare and life sciences.

More... »

Synchrogenix appoints two new global submissions directors

Monday, October 27, 2014 01:30 PM

Synchrogenix Information Strategies, a regulatory writing company headquartered in Wilmington, Del., has added two new global submissions directors: Kelley Hill and Aaron Bernstein.

More... »

Cubist Pharmaceuticals names Robert J. Perez CEO

Thursday, October 23, 2014 03:47 PM

Cubist Pharmaceuticals has selected Robert J. Perez as the company's CEO, effective January, 2015. Perez, who currently is Cubist's president and chief operating officer, will succeed Michael W. Bonney who is retiring from his current role as CEO on Dec. 31, and will become non-executive chair of Cubist's board of directors. Current board chair Kenneth M. Bate will become lead independent director.

More... »

Subscribe to The CenterWatch Monthly
CWWeekly

February 23

Venture capital investors funding novel drug R&D three times more than companies repurposing, improving existing drugs

In appreciation: Karen Woodin will be remembered for her teaching, writing and lasting friendships

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs